The incidence of TS is at 15 to 20 business pkc delta of 100,000 women per year Protected. Endometrial cancer is typically in Type I and II clinical categories of behavioral and morphological Ph Genotype-based, split with a good correlation with molecular findings. Be the onset of symptoms, explained rt Why most cases Cases diagnosed at an early stage when the disease is still nkt Descr on the uterus And has a high percentage of survival. However, a subgroup of aggressive endometrial tumors Ph Provide genotype, by lymphovaskul Marked re-invasion, high histological quality, and myometrial invasion in which a poor prognosis. over 25% of patients who undergo surgical staging to have an ectopic disease. carcinomaspreads endometrium, especially in the pelvic and para-aortic lymph nodes and Anh length and pelvic organs, with distant metastases by h matogene a low incidence. The mechanisms involved in this aggressive transformation and distribution largely unknown. Froma clinical parp1 perspective, one obtains HtesRisiko of relapse than patients with tumors that are deep in the cervical stroma myometriumor or extrauterine spread and patients with uterine papillary- Ren these defined Invade sen carcinoma or clear cell carcinoma, represents a therapeutic challenge. Surgical treatment remains the cornerstone of treatment benefit, and in particular the high-risk patients, pelvic lymphadenectomy and staging of the completions Ndigen seem para-aortic with adjuvant ma Tailored to the results of the dissection. Today, the treatment of advanced disease, chemotherapy, radiotherapy or a combination of both, the decisions about the presence of risk factors. In recent years there has been a renewed interest in integration of chemotherapy in the treatment paradigm for women with endometrial cancer. For patients with advanced disease with a combination of chemotherapy with cisplatin and doxorubicin proved to be superior to radiotherapy.
New drugs such as paclitaxel have shown promising response rates and survival in patients with endometrial cancer as monotherapy or in combination with cisplatin / carboplatin and doxorubicin chemotherapy. It remains to be seen whether adjuvant chemotherapy in patients with a high risk of disease in a lower level will improve the survival and perhaps replace the adjuvant radiotherapy in selected Be hlten patient groups. Interestingly, several targeted therapies, including mTOR, EGFR and VEGF inhibitors, for subgroups patients.Nevertheless promising, and as the most intimate of other cancers, the molecular pathways involved in development and progression of endometrial very complex and high-penetrance genes and complex interactions between multiple genes of low penetrance. To establish, despite big efforts he to the pathogenesis of endometrial cancer, the key molecular events that are not yet defined for tumor invasion and dissemination clear. Win a aper To develop molecular Ver U Changes in the progression and invasion of endometrial cancer have involved us the opportunity to develop new therapeutic Ans tze To inhibit the proliferation of the tumor and improve outcomes in patients at high risk of endometrial cancer offer. The aim of this study was to characterize the.